Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
RPTH Journal shared on LinkedIn:
”In newly diagnosed multiple myeloma patients on immunomodulatory drugs, VTE and bleeding risks remain high.
Direct oral anticoagulants showed a trend toward lower VTE vs aspirin/no prophylaxis, but bleeding rates were similar across all strategies.
Check out the full article for more details.”
Read the full article in RPTH.
Article: Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis
Authors: Lea Vospernik, Hermine Agis, Cihan Ay, Lina Rüsing, Heinz Gisslinger, Christina Brunbauer, Clara Sophie Michel, Ingrid Simonitsch-Klupp, Alexandra Kaider, Maria-Theresa Krauth, Julia Riedl

Stay updated on all scientific advances in the field of clotting disorders with Hemostasis Today.
-
Nov 19, 2026, 05:54Global Collaboration in Hemostasis – ISTH
-
Nov 19, 2026, 05:40Pete Stibbs: Advancing Treatment Strategies in Venous Disease
-
Nov 19, 2026, 05:31Lance Reed: One Donation, Multiple Lives
-
Nov 19, 2026, 05:20ZPI Silencing as a Novel Non-Factor Therapy for Rare Bleeding Disorders – HITh
-
Nov 19, 2026, 04:48Antiphospholipid Antibodies and Stroke Management – RPTH
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency